In-vivo challenge trials
Enteric® suppresses a clinical infection of necrotic enteritis when the birds are challenged with coccidiosis & Clostridium perfringens infection.
PERFORMANCE trials
In regular broiler trials Enteric® suppresses subclinical necrotic enteritis and improvements in animal performance and litter quality are observed.
Enteric® Recommendation
Application of Enteric® during whole feed cycle, Enteric® dry at 500 g /t feed or Enteric® HC dry at 50 g/t feed.
Enteric® KEY BENEFITS
- Production of a biocide with specific activity against Clostridium perfringens
- Lowering the impact of necrotic enteritis while maintaining a balanced GI tract
- Allows for more effective nutrient absorption
- Raising the birds in an AGP free programme
- Enteric® improves profit margin through better live weight gain and feed conversion.
Enteric® mode of action
No. 1 in poultry production
A disrupted gut will quickly lead to sub clinical necrotic enteritis which is a widespread problem in the poultry industry. It is known as a serious profit killer. The industry has been evaluating several routes to lower the incidence of sub clinical necrotic enteritis.
Enteric® is a unique active microbial that was selected for its targetted activity against Clostridium perfringens*. It was isolated from the gut of a healthy chicken. Several trials have demonstrated the activity of Enteric® in broilers.
*Certain statements may not be applicable in all geographical regions. Product labeling and associated claims may differ based upon government requirements.